Consistent with this association, osimertinib lost its ability to reduce DR4 levels in several osimertinib-resistant EGFRm NSCLC cell lines with distinct resistance mechanisms, including HCC827/AR (MET gene amplification and protein hyperactivation), PC-9/3M (C797S mutation) and PC-9/AR (unknown mechanisms). This evidence concerns the gene MET and non-small cell lung carcinoma.